USA S&P Global Composite PMI for Jun 52.300 vs 51.200 consensus estimate. The prior reading was 51.200.
HC Wainwright & Co. Maintains Buy on Genmab, Lowers Price Target to $46
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Genmab (NASDAQ:GMAB) with a Buy and lowers the price target from $51 to $46.